Peripheral Levels of Renin-Angiotensin System Components Are Associated With Cognitive Performance in Huntington’s Disease
Open Access
- 18 December 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 14
Abstract
The renin-angiotensin system (RAS) has proven to be involved in the pathophysiology of neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD), serving as a potential therapeutic target and a disease burden marker. Studies have associated negative clinical outcomes with the activation of the classical RAS arm composed of the angiotensin-converting enzyme (ACE) and angiotensin (Ang) II, while suggested positive outcomes with the activation of the counter-regulatory RAS arm involving ACE2 and Ang-(1–7). Huntington’s disease (HD) shares many pathological and clinical outcomes with AD and PD, but the evidence of direct involvement of RAS components in the pathophysiology of HD is still limited and needs further investigation. Herein, we investigated peripheral levels of the RAS components Ang II, Ang-(1–7), ACE, and ACE2 in controls, premanifest, and manifest HD gene carriers and their relationship with clinical outcomes. Peripheral blood samples were collected via phlebotomy, and plasma concentrations of RAS components were measured by Enzyme-Linked Immunosorbent Assay. Clinical evaluation included a questionnaire about socio-demographic characteristics, motor, and cognitive assessments. Results showed (1) no significant group differences in plasma concentrations of RAS components; (2) positive correlations between ACE2 and Verbal Fluency Test (VFT) scores; and (3) negative correlations between Ang II and Mini–Mental State Examination scores. These results corroborate the proposed balance between the classical (ACE/Ang II) and the counter-regulatory [ACE2/Ang-(1–7)] arms of the RAS, with the former associated with negative clinical outcomes and the latter with positive effects in HD.Keywords
This publication has 35 references indexed in Scilit:
- Huntington's disease: from molecular pathogenesis to clinical treatmentThe Lancet Neurology, 2011
- CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approachesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010
- Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7)American Journal of Physiology-Heart and Circulatory Physiology, 2007
- Physiology of Local Renin-Angiotensin SystemsPhysiological Reviews, 2006
- Interrater agreement in the assessment of motor manifestations of Huntington's diseaseMovement Disorders, 2005
- Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated miceEuropean Neuropsychopharmacology, 2005
- Angiotensin I converting enzyme in cerebrospinal fluid of patients with neurological diseasesJournal of Molecular Medicine, 1987
- Changes in Nine Enzyme Markers for Neurons, Glia, and Endothelial Cells in Agonal State and Huntington's Disease Caudate NucleusJournal of Neurochemistry, 1986
- Huntington's chorea: Selective depletion of activity of angiotensin converting enzyme in the corpus striatumAnnals of Neurology, 1977
- “Mini-mental state”Journal of Psychiatric Research, 1975